Baillie Gifford & Co
AMRX icon

Baillie Gifford & Co’s Amneal Pharmaceuticals AMRX Stock Holding History

Baillie Gifford & Co’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-853
Closed -$4K – 491
2022
Q1 		$4K Buy
853
+401
+89% +$1.78K ﹤0.01% 473
2021
Q4 		$2K Hold
452
– – ﹤0.01% 493
2021
Q3 		$2K Hold
452
– – ﹤0.01% 487
2021
Q2 		$2K Hold
452
– – ﹤0.01% 468
2021
Q1 		$3K Sell
452
-65
-13% -$360 ﹤0.01% 440
2020
Q4 		$2K Buy
+517
New +$2.29K ﹤0.01% 426

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co's AMRX Position: Q2 2022 in Review

Baillie Gifford & Co sold out of Amneal Pharmaceuticals (AMRX) in Q2 2022, closing a stake of 853 shares — an estimated $4K sold.

Baillie Gifford & Co first reported a position in AMRX in Q4 2020 and held it in 6 quarters. The position peaked at $4K in Q1 2022. 153 funds tracked by Wall St. Rank hold AMRX as of Q2 2022.

  • Baillie Gifford & Co reported no remaining Amneal Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Baillie Gifford & Co sold 853 Amneal Pharmaceuticals shares in Q2 2022, an estimated $4K.
  • Baillie Gifford & Co first reported a position in Amneal Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Baillie Gifford & Co's Amneal Pharmaceuticals position peaked at $4K in Q1 2022.
  • 153 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2022.

Based on Baillie Gifford & Co's 13F filing for Q2 2022, filed 8 Aug 2022.